Skip To Main Content
Mark Linch on Muck Rack

Mark Linch

As seen in: Nature, European Urology, UroToday, RadcliffeCardiology.com
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Mark Linch’s profile

Articles by Mark Linch

A preinvasive regulatory T cell axis for lung cancer interception

|
By Zoe Whiteman, Marta Lebrusant-Fernandez, Andrei Enica, Teerapon Sahwangarrom, Amber Rogers, Petros Fessas, Chuen Ryan Khaw, Lukas Kalinke, Constantin Ahlmann-Eltze, Kate Otter, Krupa Thakkar, Betty Gration, Imran Uddin, Ellen Nuttall Musson, Kyren A. Lazarus, Moritz J. Przybilla, Adam Pennycuick, Helen Hall, Charlotte Percival, Ruth Prendecki, Sophie Tisi, Georgia Constantinou, Pascal F Durrenberger, Kate Gowers, Mark Linch, Kevin Litchfield, Se-Hoon Lee, Sergio A Quezada, Peter Campbell, Jennifer Beane, Sarah A. Mazzilli, David Moore, Vitor H. Teixeira, Vítor Teixeira, Sandra Gómez-López, Bart Vanhaesebroeck, Sam M. Janes, James L. Reading, Samuel Gamble, Claudia Peinador-Marín, Abigail Y. L. Shurr, Ahmed S. N. Alhendi, Xiuchuan Hu, Zoe Hagel, Elspeth M. Payne
| Nature Verified
Abstract Late-stage non-small cell lung cancer (NSCLC) is rarely curable1, underscoring a need to intervene earlier in the disease process. Growing evidence suggests that antitumour T cell responses are mounted but become progressively dysregulated during early tumorigenesis2,3. Tracking and targeting preinvasive T cell regulation may inform new approaches to detect and intercept lung cancer development.
Open in Who Shared Issue with article?

Phase 1b trial of Bavdegalutamide (ARV-110) in combination with Abiraterone for metastatic prostate cancer.

|
By Martin Smoragiewicz, Alice Bernard-Tessier, Mark Linch
| UroToday Verified
Resistance to androgen receptor pathway inhibitors (ARPIs) necessitates development of regimens to improve outcomes in metastatic prostate cancer (mPC). This phase 1b clinical trial evaluated safety/tolerability and pharmacokinetics of bavdegalutamide, an oral PROteolysis TArgeting Chimera (PROTAC) androgen receptor (AR) degrader, combined with abiraterone in patients with mPC experiencing prostate-specific antigen (PSA) progression on abiraterone.
Open in Who Shared Issue with article?

Combined ctDNA and serum PSA for dynamic monitoring of metastatic prostate cancer starting first-line treatment: a prospective national cohort study

|
By Anuradha Jayaram, Alison Reid, Francesco Orlando, Leila Zakka, Miriam Gonçalves, Constantine Alifrangis, Rob Jones Verified, Sarah H. Needleman, Diletta Bianchini, Anna Wingate, Kenrick Ng, Mark Linch, Ursula McGovern, John Staffurth, Simon J Crabb, Alison Birtle, Osvaldas Vainauskas, Gianmarco Leone, Allan Hackshaw, Andre Romualdo Lopes, André D. Lopes, Daniel Wetterskog, Francesca Demichelis, Gerhardt Attard, Memuna Rashid, Suparna Thakali, Jacqueline O’Dwyer, Elias Pintus, Susannah Brock, Millenn Chiwewe
| Nature Verified
Abstract The prognosis of newly diagnosed metastatic prostate cancer is highly variable. The primary objective of the PARADIGM prospective cohort study was to evaluate predictors of survival in blood collected at the start of each of the first six treatment cycles from 114 patients with high-volume metastatic prostate cancer (biologically male) who were starting androgen deprivation therapy in combination with docetaxel or an androgen receptor pathway inhibitor.
Open in Who Shared Issue with article?

Cardiac Issues in Prostate Cancer

|
By Arjun K Ghosh, Mark Linch, Darryl Leong
| RadcliffeCardiology.com Verified
Overview The treatment of prostate cancer can have a significant detrimental impact on the cardiovascular system. So, when is the right time for the oncologist to call the cardiologist – before, during or after treatment or maybe at all the timepoints? This 45 minute broadcast with 10 minute live Q&A is presented by Dr Mark Linch (UCLH, London, UK) and Dr Darryl Leong (McMaster University, CA) with Dr Arjun Ghosh (Barts, London, UK) as moderator.
Open in Who Shared Issue with article?

Cardiovascular Complications of Prostate Cancer Therapy

|
By Mark Linch, Courtney Campbell, Andrew Collier MD, Avirup Guha MD
| link.springer.com
Abstract Purpose of review With treatment advances, the most common cause of death in prostate cancer patients is cardiovascular disease. Discerning the contribution of prostate cancer treatment on cardiovascular complications versus the natural progression of cardiovascular disease remains an ongoing area of investigation. Evaluating the research and identifying opportunities for further investigation is critical for optimal care of this prostate cancer patient population.
Open in Who Shared Issue with article?

Corticosteroids for Urological Cancer Care During Coronavirus Disease 2019. Treat or Not to Treat?

|
By James Hull, Jasmin V. Waterhouse, Mark Linch
| European Urology Verified
The current World Health Organization guidance is not to start corticosteroids, but there is no robust evidence of risk in patients with cancer and coronavirus disease 2019. A risk-benefit analysis should be performed for each patient on the use of steroids in cancer care. Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a ribonucleic acid (RNA) virus first identified in Wuhan, China, in December 2019 [1x[1]World Health Organization.
Open in Who Shared Issue with article?
Show More